Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
about
'Acute myeloid leukemia: a comprehensive review and 2016 update'Future prospects of therapeutic clinical trials in acute myeloid leukemia.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionMolecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer.Acute myeloid leukemia: advancing clinical trials and promising therapeutics.Isocitrate dehydrogenase mutations in myeloid malignancies.Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience.Acute myeloid leukemia--major progress over four decades and glimpses into the future.Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Targeting cancer cell mitochondria as a therapeutic approach: recent updates.IDH mutations in cancer and progress toward development of targeted therapeutics.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas.Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models.Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.Glioblastoma and acute myeloid leukemia: malignancies with striking similarities.The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Targeting Metabolism for Cancer Therapy.Emerging molecular predictive and prognostic factors in acute myeloid leukemia.The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.Treatment of relapsed/refractory acute myeloid leukaemia in adults.Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.Influence of IDH on FLT3-ITD status in newly diagnosed AML.Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations.Clinical and biological implications of in acute myeloid leukemia withWhen to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
P2860
Q28072539-BC7A7875-F656-42AD-BB7F-F3A473B0F183Q30244168-F7E94D43-8325-42F7-A704-40E4A9DAD080Q33702409-2E1D0667-9C37-4B4F-9CD8-AE2154DDDF35Q36522731-1F5A66AC-1197-4975-9DDA-D6116D824508Q36805635-0D399B7D-A828-421E-A0C8-E08CC9B1207CQ37221579-5E353155-4F11-4219-AB5A-36D7D286CEC0Q37625630-EB543420-0C83-4A21-ACE5-5F9AD3BEBDBBQ38636146-6642494D-6D6F-4592-86C1-9AF939C5821DQ38644941-F5E0DB7A-08D7-428C-A13E-6B852058D138Q38666159-0E46B21F-4A4A-4D63-8A4D-D6AEE0B83192Q38668524-FD9B1734-B20E-46CA-9D0F-6A612DBE84A0Q38785528-8A2C1494-FCCD-4EA4-9E7C-02ECF93B0EADQ39175665-CB9AF904-C931-425B-BED4-CEE6E2768C9BQ40103401-B8948FD6-B636-4A53-B3B7-C30868D930BBQ41530079-6BA3D568-A85D-4B5D-AD21-47375043D318Q41828194-7FC37B5C-71D5-44AE-9A5D-2D2C4618CDE3Q46175272-0D566776-24FD-4C57-AA5C-50059E592BA8Q47139135-699EA9BA-BD7D-4A42-B0EC-0CEEAE30FB31Q47290687-5FF6BA49-71C1-4F25-B0C1-F353860474CEQ47339574-340837B0-601F-401C-9BEC-83C451E98F0BQ47579728-9950F6FD-1BE7-4AF6-B768-7E63759A8E44Q47646742-70AB1762-715A-4195-80BD-777D5D999A83Q47670541-D4BACAE0-DBA7-43D5-8C9A-17C25257BFA9Q47728815-D8AB0555-53DB-43B2-966A-774D67AB7AA2Q47741553-B150BBBE-E02E-4C3B-A992-92342388931DQ48233351-CE97DD4C-E686-400E-8EE9-E97BAABB424FQ48622093-5178C2BD-46CF-4915-970F-21EB4F72F4DFQ52603735-5378466F-9713-4CBC-9B05-B2775933E27EQ54990383-AF13F1DF-A73E-4700-A8C1-BBAA21EB7023Q55038084-A5BC83BD-E85F-4A1F-B184-53B843D8D3F4Q55515402-9412F7C5-2A7A-4106-8F6E-841ADE712A3EQ58799268-8421196C-255B-4E1C-A022-47EB2ACDD707Q59133388-66ABDD69-AF38-48A0-916D-A70BE7DFC860
P2860
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@ast
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@en
type
label
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@ast
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@en
prefLabel
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@ast
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@en
P2093
P2860
P50
P356
P1476
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
@en
P2093
Courtney D DiNardo
Guillermo Garcia-Manero
Keyur P Patel
Koichi Takahashi
Mark Brandt
Mark Routbort
Sam Agresta
P2860
P304
P356
10.1002/AJH.24072
P577
2015-08-01T00:00:00Z